AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03045523
Drug: GLPG2222 150 mg q.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
Trial: NCT03045523
Drug: GLPG2222 300 mg q.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
Trial: NCT03045523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
Trial: NCT04147325
Drug: Antiretroviral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
Trial: NCT02206035
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m\^2 Days +3, +6 and +11.
Trial: NCT00751842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected subcutaneously at days 1, 30, 90 and 270.
Trial: NCT00928174
Drug: IV administration of fluorine-18 fluorocholine followed by PET/CT imaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
Trial: NCT01339741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral route, 12 weeks
Trial: NCT03478163
Drug: Clindamycin 900 MG in 6 ML Injection
RxNorm normalized name: clindamycin 900 MG in 6 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 900 mg every 8 hours for 3 doses
Trial: NCT02292043
Drug: HTEA
RxNorm normalized name: Hydrocortisone Tetraacetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTEA
Trial: NCT05301010
Drug: Faceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
Trial: NCT04063163
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01340053
Drug: RDX5791
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, QD
Trial: NCT02580591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For blinding purposes
Trial: NCT01124162
Drug: Cozaar®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Tablet
Trial: NCT01176799
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
Trial: NCT02273414
Drug: BIIL 284 BS - rising dose
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02273414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01176799
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
Trial: NCT00802009
Drug: Mepivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anesthetic solution administered during routine brachial plexus nerve blockade.
Trial: NCT01966289
Drug: CY
RxNorm normalized name: CYT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CY is administered intravenously at 200 mg/m2
Trial: NCT03594331
Drug: High-dose PvP001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose PvP001
Trial: NCT03594331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL liquid with no drug
Trial: NCT02534896
Drug: Treatment I
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunpharma1505 and Placebo
Trial: NCT02534896
Drug: Treatment II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunpharma1505 and Placebo
Trial: NCT02534896
Drug: Treatment III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference1505 and Placebo
Trial: NCT01641809
Drug: GSK1265744 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
Trial: NCT00465751
Drug: chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chenodeoxycholic acid 500 mg capsules tid po
Trial: NCT00465751
Drug: placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules containing mannitol tid po
Trial: NCT01641809
Drug: GSK1265744 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
Trial: NCT01641809
Drug: GSK1265744 60 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
Trial: NCT01641809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
Trial: NCT01891435
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after giving medicine temperature is checked every 30 minutes for 2 hours
Trial: NCT01891435
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after giving medicine temperature is checked every 30 minutes for 2 hours
Trial: NCT01891435
Drug: Intramuscular diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after giving medicine temperature is checked every 30 minutes for 2 hours
Trial: NCT00245037
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This drug is used to prevent seizures while on chemotherapy.
Trial: NCT00245037
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
Trial: NCT01717768
Drug: TSX-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSX-002 are capsules with testosterone as the active ingredient.
Trial: NCT00078754
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine capsules by mouth, up to 60 mg daily
Trial: NCT00330850
Drug: PRO-513
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03346941
Drug: DAA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral-based treatment
Trial: NCT01561742
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline will be given orally at 200 mg a day for 4 months
Trial: NCT01561742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EquivalentPlacebo will be given
Trial: NCT01032382
Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application to CL lesions once daily for 20 days
Trial: NCT01032382
Drug: Paromomycin Alone Cream (15% paromomycin topical cream)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application to CL lesions once daily for 20 days
Trial: NCT01051700
Drug: GW786034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product
Trial: NCT02823626
Drug: Spironolactone and patiromer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose spironolactone with or without patiromer based on the patient's baseline potassium
Trial: NCT00635726
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
Trial: NCT00635726
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
Trial: NCT02564939
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double-blind RCT
Trial: NCT03570541
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every six hours postoperative, all patients are administered 1 g of acetaminophen.
Trial: NCT04124705
Drug: Armour® Thyroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
Trial: NCT04124705
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally once a day; the daily dose could range from 25- 200 µg.
Trial: NCT01436474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
Trial: NCT02821468
Drug: Droglican
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
Trial: NCT00209703
Drug: l-Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03595592
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin will be delivered i.v. on day 1 every 3 weeks in arm ACy followed by HPCT for the first 3 cycles
Trial: NCT03595592
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab for the first 3 cycles
Trial: NCT01283698
Drug: Reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator,once daily
Trial: NCT01973998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive substance.
Trial: NCT00722956
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg once daily, 10 days
Trial: NCT00042406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered as a subcutaneous infusion twice (BID) with 2 weeks interval followed by administration every 4 weeks up to Week 22.
Trial: NCT02877303
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02877303
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00564018
Drug: NPH
RxNorm normalized name: ZENPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
Trial: NCT02877303
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02877303
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, and PO
Trial: NCT04115098
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Trial: NCT04115098
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Trial: NCT04115098
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam 7.5 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Trial: NCT01702246
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg, orally, once daily for 3 months
Trial: NCT01597713
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of oral placebo within each dose group
Trial: NCT03161522
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
Trial: NCT03161522
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
Trial: NCT02259907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02896504
Drug: Exposure: Adjuvant chemotherapy treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00312533
Drug: Hylan F- 20
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03933774
Drug: Tretinoin 0.05% cream
RxNorm normalized name: TRETINOIN 0.05% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stieva-A Cream 0.05%, 25g, GSK
Trial: NCT03933774
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
Trial: NCT02411578
Drug: G-Pen Mini™ (glucagon injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 150 µg of glucagon~2. BG is 40-49 mg/dl, treatment is 300 µg of glucagon~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 150 µg of glucagon~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(150 µg of glucagon per syringe)
Trial: NCT03787225
Drug: NNC0174-0833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.
Trial: NCT03787225
Drug: Placebo (NNC0174-0833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NNC0174-0833 matched placebo subcutaneously.
Trial: NCT01241097
Drug: simvastatin, combined with simvastatin ezetimibe, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
Trial: NCT02440243
Drug: Purethal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prerseasonal course of SCIT - three years
Trial: NCT02440243
Drug: Purethal -placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preseasonal course of SCIT - three years
Trial: NCT00351065
Drug: SK3530
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01518374
Drug: Florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 370 MBq (10 mCi)
Trial: NCT03688464
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Trial: NCT03688464
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Trial: NCT01870505
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03682692
Drug: ACEI/CCB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
Trial: NCT03682692
Drug: ACEI/DIU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
Trial: NCT03200340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match EC-18 capsule administration
Trial: NCT02783183
Drug: YHD1119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 by 2
Trial: NCT01013766
Drug: GSK1362885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg in the AM, 100mg in the PM, 50mg BID
Trial: NCT01013766
Drug: GSK1362885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg in the PM, 100mg in the AM, 50mg BID
Trial: NCT02374021
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
Trial: NCT00207129
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
Trial: NCT03068754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for subcutaneous injection
Trial: NCT05138913
Drug: TXA
RxNorm normalized name: TXA>2<
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the arthroscopic operation was completed, a local TXA injection was performed
Trial: NCT01895946
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
Trial: NCT01895946
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
Trial: NCT02915978
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl delivered via sublingual spray
Trial: NCT02915978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo delivered via sublingual spray
Trial: NCT01201187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1T/twice a day(bid) for 8weeks, po medication
Trial: NCT02496910
Drug: YH22162
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02781584
Drug: FIR
RxNorm normalized name: Firox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily
Trial: NCT02781584
Drug: VAS
RxNorm normalized name: Vasad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally two times daily
Trial: NCT02496910
Drug: Chlorthalidone 25mg
RxNorm normalized name: CHLORTHALIDONE 25MG TAB
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02205242
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
Trial: NCT02205242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no